BioPharma Dive20h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
UBS Sticks to Their Hold Rating for AstraZeneca (AZN)
UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...
Guggenheim Sticks to Their Buy Rating for AstraZeneca (AZN)
In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
Pharm Exec13h
Spravato’s Transformative Impact: Offering Hope and Rapid Relief for Patients with Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Johns Hopkins Medicine20h
Computer Model Helps ID Cancer-Fighting Immune Cells Key to Immunotherapy
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...
Frontiers3h
Combination Immune Therapies for the Treatment or Prevention of Breast or Gynecological Cancers
Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...